Corvus Pharmaceuticals Inc., of Burlingame, Calif., presented updated biomarker results from CPI-444, an adenosine A2A receptor antagonist at the Immuno-Oncology 360° Conference in New York during the "Discovery & Preclinical Science Plenary" session, which focused on tumor microenvironment-changing technologies, pegylated cytokines and additional discovery and preclinical data.